The Ozempic and GLP-1 Consumer Tracker by CivicScience
Few consumer trends today have the potential to send shockwaves across the economy and consumer markets, like the proliferation of Ozempic and other GLP-1 weight loss drugs.
Industries from healthcare to retail to food service to fitness to even travel and apparel stand to be massively disrupted as the awareness, usage, and behavioral changes resulting from these medications accelerate.
CivicScience is introducing the first large-scale, ongoing tracking and forecasting report on the rise of GLP-1 drugs among U.S. consumers and its impact on consumption, healthcare, and lifestyle behaviors.
Every month, we will survey a representative sample of over 50,000 U.S. adults about Ozempic and other GLP-1 medications, producing a comprehensive report on:
Trended awareness, usage, satisfaction, and intent
Demographic and psychographic profiling of users and intenders
Key trends in retail, food, food service, alcoholic beverage, healthcare utilization and intent, fitness and services, travel, and lifestyle among GLP-1 users
Over 4 million U.S. survey responses daily
Over 500K searchable and cross-able questions, hundreds added daily
Advanced AI capabilities, tools, and professional services
Proven predictive power and quantifiable marketing ROI
